<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744379</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA594-125</org_study_id>
    <nct_id>NCT01744379</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Study in Japanese</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of Lesinurad in Healthy Male Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the safety, tolerability, and serum uric acid lowering effect of&#xD;
      lesinurad in healthy Japanese males to allow comparison with the Western population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While there is extensive clinical experience with lesinurad in the Western population, it is&#xD;
      recognized that both intrinsic and extrinsic factors may impact the PK, PD, safety, and dose&#xD;
      response in different ethnic populations. The purpose of this study is to explore the safety,&#xD;
      tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of single and multiple doses of&#xD;
      lesinurad in healthy Japanese males, and to allow comparison of these parameters with the&#xD;
      Western population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events and Changes in Laboratory Parameters</measure>
    <time_frame>5 to 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile of lesinurad from plasma and urine in terms of AUC, tmax, cmax and t1/2.</measure>
    <time_frame>Day -1 through 12</time_frame>
    <description>AUC: area under the plasma concentration time curve from zero to 24 hours post dose and from zero to infinity; tmax: time to maximum plasma concentration; cmax: maximum observed plasma concentration t1/2: terminal elimination half life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic (PD) profile of lesinurad from serum and urine in terms of sUA concentration, renal clearance, urine uric acid excretion, and fractional excretion.</measure>
    <time_frame>Day 1 through 12</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>200 mg lesinurad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg lesinurad or placebo fasted and fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg lesinurad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg lesinurad or placebo fasted and fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg lesinurad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg lesinurad or placebo fasted and fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg lesinurad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg lesinurad or placebo fasted and fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg lesinurad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg lesinurad or placebo fasted and fed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lesinurad</intervention_name>
    <arm_group_label>100 mg lesinurad</arm_group_label>
    <arm_group_label>200 mg lesinurad</arm_group_label>
    <arm_group_label>400 mg lesinurad</arm_group_label>
    <arm_group_label>50 mg lesinurad</arm_group_label>
    <arm_group_label>600 mg lesinurad</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>100 mg lesinurad</arm_group_label>
    <arm_group_label>200 mg lesinurad</arm_group_label>
    <arm_group_label>400 mg lesinurad</arm_group_label>
    <arm_group_label>50 mg lesinurad</arm_group_label>
    <arm_group_label>600 mg lesinurad</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand the study procedures, the risks involved and willing to provide&#xD;
             written Informed Consent before the first study related activity.&#xD;
&#xD;
          -  Healthy adult subjects born in Japan&#xD;
&#xD;
          -  All laboratory parameters should be within normal limits or considered not clinically&#xD;
             significant by the investigator.&#xD;
&#xD;
          -  Screening serum uric acid level &gt;= 4.5 mg/dL.&#xD;
&#xD;
          -  Subjects must be free of any clinically significant disease that requires a&#xD;
             physician's care and/or would interfere with study evaluations or procedures.&#xD;
&#xD;
          -  Subject does not have clinically relevant abnormalities in blood pressure, heart rate,&#xD;
             body temperature, and respiratory rate, as per the Investigator's judgment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive serology to Human Immunodeficiency Virus (HIV-1 and HIV-2).&#xD;
&#xD;
          -  Positive test for active Hepatitis B or Hepatitis C infection.&#xD;
&#xD;
          -  History of kidney stones.&#xD;
&#xD;
          -  Undergone major surgery within 3 months of Day 1.&#xD;
&#xD;
          -  Subject has received the last dose of an investigational drug (or treatment with a&#xD;
             medical device) within 30 days or 5 half-lives (whichever is longer) of the&#xD;
             investigational drug prior to Day 1 or are currently participating in another study of&#xD;
             an investigational drug (or medical device).&#xD;
&#xD;
          -  Prior exposure to lesinurad (RDEA594) or RDEA806.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S Bradley, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 29, 2012</study_first_submitted>
  <study_first_submitted_qc>December 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lesinurad</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

